Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The study's primary endpoint of progression ... the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion ...

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.Most Read from BloombergCitadel to Leave Namesake Chicago T ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...